Naazish S Bashir1,2, Thomas D Walters3,4, Anne M Griffiths3,4, Shinya Ito4,5, Wendy J Ungar1,2. 1. Program of Child Health Evaluative Sciences, The Hospital for Sick Children Research Institute, Toronto, Ontario, Canada. 2. The Institute of Health Policy, Management and Evaluation, The University of Toronto, Toronto, Ontario, Canada. 3. Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Ontario, Canada. 4. Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada. 5. Division of Clinical Pharmacology, Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, Ontario, Canada.
Abstract
BACKGROUND: Anti-tumor necrosis factor-α (anti-TNF-α) treatments are increasingly used to treat pediatric Crohn's disease, even without a prior trial of immunomodulators, but the cost-effectiveness of such treatment algorithms has not been formally examined. Drug plan decision-makers require evidence of cost-effectiveness to inform funding decisions. The objective was to assess the incremental cost-effectiveness of early intervention with anti-TNF-α treatment vs a conventional step-up strategy per steroid-free remission-week gained from public health care and societal payer perspectives over 3 years. METHODS: A probabilistic microsimulation model was constructed for children with newly diagnosed moderate to severe Crohn's disease receiving anti-TNF-α treatment and concomitant treatments within the first 3 months of diagnosis compared with children receiving standard care consisting of steroids and/or immunomodulators with the possibility of anti-TNF-α treatment after 3 months of diagnosis. A North American multicenter observational study with 360 patients provided input into clinical outcomes and health care resource use. RESULTS: Early intervention with anti-TNF-α treatment was more costly, with an incremental cost of CAD$31,112 (95% confidence interval [CI], $2939-$91,715), and more effective, with 11.3 more weeks in steroid-free remission (95% CI, 10.6-11.6) compared with standard care, resulting in an incremental cost per steroid-free remission-week gained of CAD$2756 from an Ontario public health care perspective and CAD$2968 from a societal perspective. The incremental cost-effectiveness ratio was sensitive to the price of infliximab. CONCLUSIONS: The results suggest that although early anti-TNF-α was not cost-effective, it was clinically beneficial. These findings, along with other randomized controlled trial evidence, may inform formulary decision-making.
BACKGROUND: Anti-tumor necrosis factor-α (anti-TNF-α) treatments are increasingly used to treat pediatric Crohn's disease, even without a prior trial of immunomodulators, but the cost-effectiveness of such treatment algorithms has not been formally examined. Drug plan decision-makers require evidence of cost-effectiveness to inform funding decisions. The objective was to assess the incremental cost-effectiveness of early intervention with anti-TNF-α treatment vs a conventional step-up strategy per steroid-free remission-week gained from public health care and societal payer perspectives over 3 years. METHODS: A probabilistic microsimulation model was constructed for children with newly diagnosed moderate to severe Crohn's disease receiving anti-TNF-α treatment and concomitant treatments within the first 3 months of diagnosis compared with children receiving standard care consisting of steroids and/or immunomodulators with the possibility of anti-TNF-α treatment after 3 months of diagnosis. A North American multicenter observational study with 360 patients provided input into clinical outcomes and health care resource use. RESULTS: Early intervention with anti-TNF-α treatment was more costly, with an incremental cost of CAD$31,112 (95% confidence interval [CI], $2939-$91,715), and more effective, with 11.3 more weeks in steroid-free remission (95% CI, 10.6-11.6) compared with standard care, resulting in an incremental cost per steroid-free remission-week gained of CAD$2756 from an Ontario public health care perspective and CAD$2968 from a societal perspective. The incremental cost-effectiveness ratio was sensitive to the price of infliximab. CONCLUSIONS: The results suggest that although early anti-TNF-α was not cost-effective, it was clinically beneficial. These findings, along with other randomized controlled trial evidence, may inform formulary decision-making.
Authors: Eric I Benchimol; David R Mack; Geoffrey C Nguyen; Scott B Snapper; Wenbin Li; Nassim Mojaverian; Pauline Quach; Aleixo M Muise Journal: Gastroenterology Date: 2014-06-18 Impact factor: 22.682
Authors: S C Blackburn; A E Wiskin; C Barnes; K Dick; N A Afzal; D M Griffiths; R M Beattie; M P Stanton Journal: Arch Dis Child Date: 2014-01-06 Impact factor: 3.791
Authors: Filip Baert; Liesbeth Moortgat; Gert Van Assche; Philip Caenepeel; Philippe Vergauwe; Martine De Vos; Pieter Stokkers; Daniel Hommes; Paul Rutgeerts; Severine Vermeire; Geert D'Haens Journal: Gastroenterology Date: 2009-10-08 Impact factor: 22.682
Authors: Robert Heuschkel; Camilla Salvestrini; R Mark Beattie; Hans Hildebrand; Thomas Walters; Anne Griffiths Journal: Inflamm Bowel Dis Date: 2008-06 Impact factor: 5.325
Authors: Frank M Ruemmele; Jeffrey S Hyams; Anthony Otley; Anne Griffiths; Kaija-Leena Kolho; Jorge Amil Dias; Arie Levine; Johanna C Escher; Jan Taminiau; Gabor Veres; Jean-Frederic Colombel; Séverine Vermeire; David C Wilson; Dan Turner Journal: Gut Date: 2014-05-12 Impact factor: 31.793
Authors: Maria M E Jongsma; Martine A Aardoom; Martinus A Cozijnsen; Merel van Pieterson; Tim de Meij; Michael Groeneweg; Obbe F Norbruis; Victorien M Wolters; Herbert M van Wering; Iva Hojsak; Kaija-Leena Kolho; Thalia Hummel; Janneke Stapelbroek; Cathelijne van der Feen; Patrick F van Rheenen; Michiel P van Wijk; Sarah T A Teklenburg-Roord; Marco W J Schreurs; Dimitris Rizopoulos; Michail Doukas; Johanna C Escher; Janneke N Samsom; Lissy de Ridder Journal: Gut Date: 2020-12-31 Impact factor: 23.059